Marco A

Clonaram o Claude Design e você pode usá-lo de graça e sem limites. Chama-se Open Design, um projeto open source que te permite usar o Claude para workflows de design sem pagar. Sem assinaturas. Sem limites (como na versão oficial). Acesso total. Isso é o que você pode fazer: — Gerar designs UI/UX com Claude — Converter prompts em designs reais — Substituir ferramentas de design caras em muitos casos — Personalizá-lo completamente (é open source) Foi feito para devs, indie hackers e criadores que não querem torrar dinheiro em ferramentas. Daqueles repositórios que passam despercebidos até que de repente todo mundo os usa. Se você usa AI + design, precisa experimentar Link abaixo 👇

INSTEAD OF WATCHING NETFLIX TONIGHT. Spend 1 hour with this. Claude AI FULL COURSE that teaches you how to BUILD and AUTOMATE anything. The people who watch this tonight will wake up tomorrow with a new skill. Watch it and Bookmark it now.

Oncology weekend shifts always have something unexpected in store for you. This poor patient was referred to our center with initially an unclear digestion disorder, before the CT scan revealed this massive tumor mass, which practically filled her whole belly. All the darkish grey areas in the photos is basically tumor. Biopsies revealed a nasty relapse of her melanoma, first removed in 2017 and in remission ever since. We now await the molecular diagnostics and especially the BRAF-mutation. If positive, we will combine two different targeted drugs by tablets with single immunotherapy, if negative she will start a dual immunotherapy.

She was my very first colorectal cancer patient 5 years ago, who received dual immunotherapy despite her tumor not primarily classifying for immunotherapy. Her cancer had spread to the lungs without any options to perform surgery. She had gone through various cycles of chemo with no meaningful effect in the end. But her tumor showed a high reading of another marker called TMB - tumor mutational burden. ✅ After 3 cycles of immunotherapy all the lung metastases were gone and she remains with no evidence of disease until today. A tremendous success story of modern personalized oncology.

In RAS-mutant mPDAC (n=40; efficacy-evaluable n=35), 1L daraxonrasib shows: ✅ ORR 51% ✅ DCR 97% ✅ 6-mo PFS 71% | OS 83% ✅ Deep ctDNA responses (100% VAF reduction; 57% clearance; n=28) ✅ Manageable safety (no G4/5 TRAEs) Encouraging early signal beyond chemotherapy. Phase 3 (RASolute-303) ongoing 🔬 @OncoAlert @Larvol @MedwatchKate #AACR26

🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…

Results from KROCUS study @TheLancetOncol: first-line fulzerasib (KRAS G12C inhibitor) + cetuximab (anti-EGFR mAb) in KRAS G12C NSCLC (n=47). RR 69%, median treatment duration 10.1m, only 6% required discontinuation due to TRAE. thelancet.com/journals/lanon…

Classically, Hepatorenal syndrome was defined as the abscence of response to 48h of albumin expansion in the absence of other causes for renal failure in cirrhotic patient. However this has been challenged on recent 2024 joint ADQI/ICA consensus linkinghub.elsevier.com/retrieve/pii/S…

@DrNikhilMD Leptospirosis

Patient with hematuria, weight loss, shortness of breath Probable diagnosis?

Robot-assisted surgery beats conventional surgery in oesophageal squamous cell carcinoma

Cisplatin ruled muscle-invasive bladder cancer for decades... EVP just ended that era regardless of cispaltin eligibility. EV + pembrolizumab vs gem/cis in MIBC: Event-free survival HR: 0.40, overall survival was HR: 0.50 This isn't just improvement. It's replacement... @NEJM @ASCO @BladderCancerUS @OncoAlert

Me, a cancer surgeon with a high risk breast clinic: What brings you in today? Patient: My grandmother had breast cancer at 60 and I was told I can’t take hormone replacement therapy even though I can’t sleep at night from the hot flashes. Me: Who told you that? Patient: A friend who had breast cancer. She said HRT caused it. Me: HRT doesn’t cause breast cancer, it slightly raises the risk. Let’s talk about your risk and how much it would go up but the benefits usually outweigh the risk. Patient (at end of visit): Oh my goodness Dr. I am so glad I came to see you. Me: HRT can help protect the brain and bones and it raises the risk of breast cancer less than the scientific community originally thought. It is safe for many women even with a family history! For all the women who will see this: Please discuss your risk factors and calculate your risk with your OBGYN / a high risk breast clinic (which may include genetic testing) and make an empowered decision.

A 240 pateint single arm trial exploring 9 cycles of EVP without planned surgery in MIBC. This will answer the key questions ‘What happens if we don’t do cystectomy in those with clinical complete response after initial EVP’.It assesses cCR rates and bladder intact EFS. It will clarify ‘EVP 1st ask questions later’ #GUtrendingTopics @OncoAlert

Not all chemo toxicity needs dose reduction. A new phase III NEJM trial shows romiplostim can prevent chemotherapy dose delays caused by thrombocytopenia. For years, chemotherapy-induced thrombocytopenia (CIT) has forced oncologists to reduce or delay treatment. This study tests whether a TPO receptor agonist can maintain dose intensity. 🧪 Trial design Phase III, double-blind RCT Patients: GI cancers on oxaliplatin-based chemotherapy with persistent CIT Randomization: Romiplostim vs placebo (2:1) N = 165 📊 Primary endpoint No CIT-related chemo dose modification in cycles 2–3 📈 Results • No chemo dose modification: 84% vs 36% • Odds ratio: 10.16 • Platelet response: 97% vs 77% • Median platelet recovery: 1.1 vs 2.1 weeks ⚠️ Safety Grade ≥3 adverse events: 37% vs 22% 🎯 Takeaway Romiplostim significantly reduces chemotherapy delays and dose reductions from thrombocytopenia, potentially preserving dose intensity in GI cancer chemotherapy. If confirmed in broader populations, this could become the first effective strategy for CIT management. 🔖 Save this for clinic. 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #GIcancer #Thrombocytopenia @OncoAlert @ASCO @myESMO @NEJM

Oncotype DX in eBC: Brazilian RWE Key findings 🔹Potential⬇️12.6% in CT indication Largest impact: • Post N1:⬇️94% • N0 ≥50y & high clin risk:⬇️65% 🔹Predictors of RS>25: • Ki67>20% | PR≤30% | G3 🔹RS < 25: excellent 5y DFS. @JCOOP_ASCO @OncoAlert @oncodaily

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. esmoopen.com/article/S2059-…

@DrHBurstein @curijoey @DrKateDibble @IEOufficiale For endocrine therapy in premenopausal pts with HR+/HER2+ eBC, don’t miss our editorial in The Breast (with Meredith Regan and @AnnPartridgeMD) 👉 thebreastonline.com/article/S0960-… 13/

🧬 Anti-PD-1 & Fertility in Melanoma What should we tell young women? 🧪 STUDY SNAPSHOT 🔍 👩‍⚕️ Women <45 yrs 🎯 Resectable stage III–IV melanoma 💉 Adjuvant nivolumab or pembrolizumab 📍 Prospective national cohort 👥 n = 17 🔬 WHAT WAS MONITORED 🧫 🧬 AMH 🟣 Antral follicle count (AFC) ⚖️ FSH | LH | Estradiol | Progesterone ⏳ Baseline → 18 months 📆 Median follow-up 5.1 yrs 📊 KEY FINDINGS ✅ 🟢 AMH stable 🟢 AFC preserved 🔄 Hormones within physiological ranges 🚫 No ovarian insufficiency signal 👶 REAL-WORLD OUTCOMES 🤍 👩‍🍼 6 pregnancies after treatment 🌿 Mostly natural conceptions ⚠️ Pregnancy seen even after endocrine irAEs 🧠 CLINICAL TAKEAWAY 💡 Adjuvant anti-PD-1 does NOT appear to impair ovarian function @OncoAlert @myESMO @ASCO @ESGO_society

💊 CAPE dosing: black box? 🧬 FDA: mandatory DPYD testing ⚠️ Complete DPD def. → avoid ❓ Partial def. (~5%) → individualize 📉 25–50% dose reduction? Limited evidence 📊 PK/PD very variable (renal, sex, surgery…) 🎯 Efficacy–exposure relation unclear 👉 Time to rethink CAPE dosing. 🔗 doi.org/10.1200/JCO-25…

PATINA is now out in @nejm. Among pts with HR+/HER2+ MBC progression-free after chemo induction, adding palbociclib to 1L ET+HER2-blockade maintenance prolonged PFS from 29 mo to an astonishing 44 months (HR 0.75, p=0.02). Congrats @Otto_DFCI & coauthors! nejm.org/doi/full/10.10…